Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
Sleeping in an MRI scanner, babies with ApoE4 genotype reveal myelination and structural differences in brain areas affected in people with Alzheimer’s disease.
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
New strategies may help find and retain participants for Alzheimer’s trials.
New research strengthens the idea that microglia do far more than scour the brain for emergencies.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Researchers Revel in C9ORF72 Advances at RNA Symposium Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS The Four Stages of TDP-43 Proteinopathy Blocking a MicroRNA Slows Motor Neuron Disease in Mice Glial Cells Refine Neural Circuits Innate Immune ...
A Conference Devoted to Better Engaging Clinical Trial Volunteers Turning to the Internet for Alzheimer’s Trial Volunteers Patient Engagement in Clinical Trials ...
New research reveals fundamental roles for astrocytes and microglia in shaping neural circuits.
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
The NIH releases whole-genome data from the Alzheimer’s Sequencing Project.